LTRN Lantern Pharma Inc.

Price Chart

Executive Summary

Lantern Pharma is conducting a dilutive public offering of 1,454,175 shares of common stock at $2.06 per share, plus 681,748 pre-funded warrants at $2.0599 each, alongside a concurrent private placement of 2,135,923 purchase warrants exercisable at $2.27. The company expects net proceeds of approximately $3.94 million for working capital, extending its cash runway to mid-Q1 2027, but this comes at the cost of immediate 19% dilution to existing shareholders and significant future overhang from the purchase warrants. The filing also discloses a going-concern risk and the need for substantial additional funding.

Actionable Insight

Key Facts

• Offering 1,454,175 shares of common stock at $2.06 per share and 681,748 pre-funded warrants at $2.0599 each.
• Concurrent private placement of 2,135,923 purchase warrants exercisable at $2.27 per share, exercisable from 6-month anniversary for 5 years.
• Net proceeds estimated at ~$3.94 million after placement agent fees and expenses.
• Immediate dilution of $1.28 per share to new investors; net tangible book value increases from $0.58 to $0.78 per share post-offering.
• As of Dec 31, 2025, total assets ~$11.04M, working capital ~$6.3M, cash and equivalents ~$10.1M.
• Auditor's report includes going-concern explanatory paragraph; company expects to need additional financing.
• Cash runway extended to approximately mid-Q1 2027 with net proceeds.
• 90-day lock-up for officers and directors; 75-day lock-up for company on further issuances.
• Placement agent fees: 7% cash fee plus warrants for 5% of shares sold at 125% of offering price.
• Stock price on May 11, 2026: $2.09 per share; 52-week range $1.11 - $5.74.

Financial Impact

~$4.4M gross proceeds; ~$3.94M net; 19% dilution from ~11.3M to ~13.4M shares outstanding (assuming full pre-funded warrant exercise).

Risk Factors

• Immediate 19% dilution to existing shareholders.
• Future dilution from 2.1M purchase warrants exercisable at $2.27 (8% above offering price) starting Nov 2026.
• Going-concern risk; company requires substantial additional funding to continue operations beyond mid-Q1 2027.
• No minimum offering requirement; offering may close with less than full amount, reducing expected proceeds.
• Pre-funded warrants have no public market; limited liquidity for those instruments.
• Stock price volatility; 52-week range $1.11 - $5.74.

Market Snapshot

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

US Market Status